Macrolides in Children With Community-Acquired Pneumonia: Panacea or Placebo?

TitleMacrolides in Children With Community-Acquired Pneumonia: Panacea or Placebo?
Publication TypeJournal Article
Year of Publication2018
AuthorsBlyth CC, Gerber JS
JournalJ Pediatric Infect Dis Soc
Volume7
Start Page71
Issue1
Pagination71-7
Date Published2018 Feb 19
ISSN2048-7207
Abstract

Pneumonia, most often caused by a respiratory virus, is common in childhood. Mycoplasma pneumoniae also is detected frequently, particularly in older children in the era of pneumococcal conjugate vaccination. Despite recommendations for β-lactam antibiotics, macrolide antibiotics, including erythromycin, clarithromycin, and azithromycin, are prescribed frequently to children with acute lower respiratory infection. However, the significance of detecting "atypical" pathogens, including M pneumoniae, in children remains contentious. Considering the potential for antibacterial and anti-inflammatory activities of macrolides, our understanding of the role of these drugs in acute and chronic infections and in inflammatory conditions is changing. Some observational data have revealed improved outcomes in adults and children with pneumonia who are prescribed macrolides, although its widespread use has led to increases in macrolide resistance in Streptococcus pneumoniae and M pneumoniae. Clinical trials to define the role of macrolides in pediatric acute respiratory infection must be prioritized.

DOI10.1093/jpids/pix083
Alternate JournalJ Pediatric Infect Dis Soc
PubMed ID29096010